Cracking the CAR T Code for Solid Tumors

AffyImmune is a clinical stage biotech company bringing the benefits of CAR T to the majority of cancer patients

Our Science

AffyImmune is developing the next generation of cellular therapies to enhance the ability of a patient’s own immune system to detect and eliminate tumor cells where ICAM-1 is overexpressed.

Affinity Tuning

With its groundbreaking approach, AffyImmune fine tunes the affinity of CAR T cells to selectively kill tumor cells while sparing healthy cells.

Noninvasive Monitoring

AffyImmune engineers CAR T cells to be monitorable – non-invasively – in patients during treatment.

Focus on ICAM-1

ICAM-1 is a master regulator of many essential cellular functions at the onset and resolution of pathological conditions. AffyImmune is focused on cancers where ICAM-1 overexpression plays a key role.

Clinical Indications

Although most thyroid cancers are curable, prognosis is very poor for anaplastic and refractory thyroid cancers (ARTC). AffyImmune's lead candidate, AIC100, is an ICAM-1-directed CAR T therapy being developed for patients with ARTC.

Featured News

May 23, 2024

AffyImmune Announces Confirmed Complete Response in Patient with Anaplastic Thyroid Cancer

November 17, 2023

AffyImmune Therapeutics Awarded Best Oncology R&D Advance Scrip Award 2023

October 3, 2023

AffyImmune Therapeutics to Present at 2023 Cell & Gene Meeting on the Mesa

September 21, 2023

AffyImmune Therapeutics Named 2023 Scrip Award Finalist for Best Oncology R&D Advance